Phreesia, Inc. (NYSE:PHR) CEO Chaim Indig Sells 3,392 Shares

Phreesia, Inc. (NYSE:PHR) CEO Chaim Indig sold 3,392 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $22.86, for a total transaction of $77,541.12. Following the completion of the transaction, the chief executive officer now directly owns 1,222,005 shares in the company, valued at $27,935,034.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Chaim Indig also recently made the following trade(s):

• On Monday, April 8th, Chaim Indig sold 12,043 shares of Phreesia stock. The stock was sold at an average price of $22.62, for a total transaction of $272,412.66.

Phreesia Stock Performance

Shares of PHR stock opened at $23.16 on Thursday. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -9.19 and a beta of 0.92. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.78 and a current ratio of 1.78. The company has a 50-day simple moving average of $24.49 and a 200 day simple moving average of $21.25. Phreesia, Inc. has a 52 week low of $12.05 and a 52 week high of $34.98.

Phreesia (NYSE:PHR) last announced its earnings results on Thursday, March 14th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.02. The business had revenue of $95.00 million during the quarter, compared to the consensus estimate of $93.52 million. Phreesia had a negative net margin of 38.42% and a negative return on equity of 53.33%. Phreesia’s revenue was up 24.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.72) EPS. On average, sell-side analysts predict that Phreesia, Inc. will post -1.48 earnings per share for the current year.

Wall Street Analyst Weigh In

PHR has been the topic of several research reports. Raymond James reaffirmed an “outperform” rating and issued a $30.00 price objective (up from $25.00) on shares of Phreesia in a research report on Friday, March 15th. Barclays started coverage on shares of Phreesia in a research report on Wednesday, January 3rd. They issued an “overweight” rating and a $29.00 price objective on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $23.00 price target on shares of Phreesia in a research note on Thursday, March 21st. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price target on shares of Phreesia in a research note on Friday, March 15th. Finally, DA Davidson reiterated a “neutral” rating and issued a $32.00 price target on shares of Phreesia in a research note on Friday, March 15th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.62.

Institutional Trading of Phreesia

A number of institutional investors have recently bought and sold shares of the business. FMR LLC boosted its holdings in Phreesia by 8.6% in the 3rd quarter. FMR LLC now owns 7,856,551 shares of the company’s stock valued at $146,760,000 after purchasing an additional 624,456 shares during the period. BlackRock Inc. boosted its holdings in Phreesia by 5.8% in the 1st quarter. BlackRock Inc. now owns 6,359,641 shares of the company’s stock valued at $167,640,000 after purchasing an additional 349,301 shares during the period. Vanguard Group Inc. boosted its holdings in Phreesia by 4.4% in the 4th quarter. Vanguard Group Inc. now owns 4,628,441 shares of the company’s stock valued at $107,148,000 after purchasing an additional 194,035 shares during the period. Brown Advisory Inc. boosted its holdings in Phreesia by 22.2% in the 4th quarter. Brown Advisory Inc. now owns 3,950,356 shares of the company’s stock valued at $91,451,000 after purchasing an additional 716,374 shares during the period. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in Phreesia by 5.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,676,879 shares of the company’s stock valued at $86,624,000 after purchasing an additional 139,410 shares during the period. Institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.